Company / R&D Expense
CUMBERLAND PHARMACEUTICALS INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$5.6M
FY2025
5-year range
$5.6M / $6.9M
FY2021-FY2025
Trend
-4.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $3M in FY2018 to $7M in FY2021.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of -0.7%.
Declined from $7M to $6M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.7%
- 5-Year CAGR
- -0.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -0.7%, indicating a declining trend.
- In FY2025, r&d expense decreased 4.6% year-over-year.
- Peak r&d expense was recorded in FY2021.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.6M | -4.6% |
| FY2024 | $5.8M | -12.8% |
| FY2023 | $6.7M | +17.7% |
| FY2022 | $5.7M | -17.2% |
| FY2021 | $6.9M | +19.0% |
| FY2020 | $5.8M | -15.9% |
| FY2019 | $6.9M | +115.3% |
| FY2018 | $3.2M | -17.1% |
| FY2017 | $3.8M | +13.5% |
| FY2016 | $3.4M | -39.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026